Dr Agarwal’s Health Care Q1 FY27: ₹565-650 Cr range

Key event: board meeting and earnings call on August 4

Dr. Agarwal's Health Care Limited has scheduled its Q1 FY27 results-related events for August 4, 2026. The company’s Board of Directors is set to meet the same day to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Alongside the board meeting, the company will host an earnings and analyst conference call on August 4, 2026 at 5:30 PM IST. For investors tracking the stock during the June-quarter results season, the date provides a clear checkpoint to assess operating momentum and profitability trends.

What the estimates indicate for Q1 FY27

A Uniresearch estimate band pegs Dr. Agarwal’s Health Care’s Q1 FY27 revenue at ₹565-650 crore. The same information set places the profit after tax (PAT) estimate at ₹39-50 crore. The estimate is described as a trailing-growth framework built on the Q1 FY26 base of ₹501 crore revenue and ₹38 crore net profit. The dataset also includes a 12-month target range of ₹551-613 under the Uniresearch estimate. These ranges are presented as an expectations framework rather than announced company guidance.

Q1 FY26 base and stated year-on-year growth rates

The estimate table explicitly uses Q1 FY26 actuals of ₹501 crore revenue and ₹38 crore PAT as the base period. Based on that, the table lists year-on-year growth of +21.2% for revenue and +17.4% for PAT. The Q1 FY27 estimate band is therefore framed as an extension of the prior-year June-quarter base. Investors typically compare such estimates with actual reported numbers to evaluate execution and whether margins held up amid network expansion and cost movements.

Prior quarter snapshot: Q4 figures referenced in the data

The information provided also includes a “Quick Details” snapshot showing the previous quarter revenue at ₹564 crore, previous quarter PAT at ₹50 crore, and previous quarter EBITDA margin at 30.2%. Separately, FY26 commentary in the dataset states Q4FY26 total income at ₹577 crore, with 21.2% year-on-year growth from ₹476 crore in Q4FY25 and 6.77% quarter-on-quarter growth from ₹540.40 crore in Q3FY26. These different lines appear to come from multiple summary blocks, and readers should map each number to its stated label before drawing comparisons.

Trading window closure ahead of results

The dataset notes that Dr Agarwals Eye Hospital Ltd has closed its trading window from June 30, 2026, ahead of the Q1 FY27 results. The closure applies to all designated persons and their immediate relatives, in preparation for finalization of the unaudited financial results for the quarter ending June 30, 2026. The trading window is stated to reopen 48 hours after the unaudited financial results are announced by the board, subject to board approval. The specific date and time of the board meeting to approve results is stated to be communicated separately, even as another line specifies the August 4 board meeting.

Results date references: July-August window and a separate May line

The estimate table lists the results date as “July-August 2026 (indicative)” for the Q1 FY27 reporting window, aligning it with the broader NSE and BSE results season for the June 2026 quarter. Separately, the dataset contains a line stating: “Upcoming Earnings date for Dr Agarwals Health Care Ltd. is 21st, May, 2026.” The information set does not clarify whether the May date pertains to a different reporting item, a prior schedule, or a different period label. With the board meeting and conference call both scheduled for August 4, that date is the clearer reference point within the provided details.

FY26 scale-up and margin context from the dataset

The dataset states the company crossed ₹2,000 crore in revenue for the first time, reporting total income of ₹2,125 crore for FY26, a 20.9% year-on-year rise. It also states EBITDA increased 22.2% year-on-year, with margins improving by 31 basis points to 28.9%. At the same time, it notes an approximate ₹30 crore loss from newly established greenfield branches during FY26, which affected overall margins. This margin context is relevant for Q1 FY27 because expansion costs can influence near-term profitability even when top-line growth remains strong.

Operational and quarterly performance markers mentioned

The dataset includes operating metrics and quarterly performance highlights for earlier periods, including surgeries and margins. It notes 81,002 surgeries in Q3FY26 with 11.2% year-on-year growth, total income of ₹540 crore, revenue from operations of ₹530 crore, EBITDA of ₹155 crore with EBITDA margin of 28.6%, and PAT of ₹44 crore with a PAT margin of 8.1%. It also states that as of September 30, 2025, the network stood at 258 facilities, with 11 new centers added during the quarter (6 secondary and 5 primary). These figures provide context on volumes, network footprint, and profitability levels cited in the information.

Valuation markers and price references provided

The “Quick Details” block lists a CMP of ₹482.2, while another line states “Dr. Agarwal’s Health Care CMP Rs.474.” The dataset also lists a 12-month target range of ₹551-613 (Uniresearch estimate). Since the CMP appears in two different places with different values, readers should treat the price references as point-in-time values from different snapshots. The more durable takeaways from the dataset are the scheduled results events, estimate ranges, and the disclosed base numbers used for year-on-year comparison.

Summary table: dates, estimates, and key reference points

Market impact: what investors will likely track in the print

The immediate market focus will be whether reported revenue and PAT track within the cited estimate bands, and whether margins reflect the expansion-related cost pressures described for FY26. The previous quarter snapshot in the dataset indicates ₹564 crore revenue, ₹50 crore PAT, and 30.2% EBITDA margin, which gives a near-term reference for sequential comparisons once Q1 FY27 numbers are published. Investors are also likely to pay attention to management commentary on the performance of newer branches, given the FY26 note of an approximate ₹30 crore loss from greenfield branches. Any updates on network additions or volume metrics, similar to the previously stated surgeries and facility counts, could shape expectations about operating leverage.

Why the event matters: the estimate framework versus actual delivery

This results announcement is positioned as a key checkpoint because the dataset frames Q1 FY27 expectations on a defined Q1 FY26 base and specified year-on-year growth rates. That makes the eventual comparison relatively straightforward: actual revenue and PAT can be checked against both the base numbers and the stated growth ranges. It also matters because the dataset includes evidence of scale-up in FY26 and margin movement, alongside the acknowledged drag from greenfield branches. The conference call timing also gives analysts an opportunity to question management on profitability drivers, cost trends, and the pace of expansion.

Conclusion

Dr. Agarwal’s Health Care has set August 4, 2026 for its board meeting on Q1 FY27 unaudited results and an earnings call at 5:30 PM IST. Uniresearch estimates in the dataset place Q1 FY27 revenue at ₹565-650 crore and PAT at ₹39-50 crore, based on Q1 FY26 actuals of ₹501 crore revenue and ₹38 crore PAT. The next confirmed step is the company’s board approval and subsequent disclosure of the unaudited standalone and consolidated results, followed by management commentary on the scheduled call.